Aduro BioTech, Inc. (ADRO) At $9.30 Forms Bottom; Wellesley Bancorp Has 1 Sentiment

Wellesley Bancorp, Inc. operates as the bank holding firm for Wellesley Bank that provides various financial services to individuals, non-profit organizations, small businesses, and other entities in eastern Massachusetts. The company has market cap of $74.21 million. The Company’s deposit products include noninterest-bearing demand deposits, such as checking accounts; interest-bearing demand accounts comprising negotiable order of withdrawal and money market accounts; savings accounts; and certificates of deposit, as well as offers remote capture products. It has a 22.84 P/E ratio. The firm also offers residential mortgage loans, commercial real estate loans, and construction loans, as well as home equity lines of credit and other consumer loans that consist of fixed-rate second mortgage loans, automobile loans, loans secured by passbook or certificate accounts, and overdraft loans; and commercial business loans, such as term loans, revolving lines of credit, and equipment loans.

Aduro BioTech, Inc. (ADRO) formed multiple bottom with $8.65 target or 7.00% below today’s $9.30 share price. Aduro BioTech, Inc. (ADRO) has $753.36M valuation. The stock increased 6.90% or $0.6 during the last trading session, reaching $9.3. About 766,625 shares traded or 29.02% up from the average. Aduro BioTech, Inc. (NASDAQ:ADRO) has risen 1.22% since March 27, 2017 and is uptrending. It has underperformed by 15.48% the S&P500.

Analysts await Aduro BioTech, Inc. (NASDAQ:ADRO) to report earnings on May, 1. They expect $-0.31 earnings per share, up 3.13% or $0.01 from last year’s $-0.32 per share. After $-0.35 actual earnings per share reported by Aduro BioTech, Inc. for the previous quarter, Wall Street now forecasts -11.43% EPS growth.

Among 10 analysts covering Aduro Biotech (NASDAQ:ADRO), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. Aduro Biotech has $68 highest and $8 lowest target. $25.61’s average target is 175.38% above currents $9.3 stock price. Aduro Biotech had 21 analyst reports since August 19, 2015 according to SRatingsIntel. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) earned “Buy” rating by Cowen & Co on Tuesday, July 18. The rating was downgraded by Oppenheimer to “Perform” on Tuesday, December 1. H.C. Wainwright maintained Aduro BioTech, Inc. (NASDAQ:ADRO) on Thursday, August 3 with “Buy” rating. Bank of America maintained the shares of ADRO in report on Friday, March 2 with “Underperform” rating. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) earned “” rating by Leerink Swann on Wednesday, August 19. The firm earned “Buy” rating on Thursday, August 27 by Roth Capital. The rating was maintained by Oppenheimer on Wednesday, December 13 with “Outperform”. The rating was maintained by Roth Capital on Tuesday, November 24 with “Buy”. FBR Capital maintained Aduro BioTech, Inc. (NASDAQ:ADRO) on Tuesday, May 17 with “Outperform” rating. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) has “Buy” rating given on Wednesday, December 13 by H.C. Wainwright.